The Economic Benefit of Remission for Patients with Rheumatoid Arthritis.

ABSTRACT:

Introduction

In patients with rheumatoid arthritis (RA), attaining remission or low disease activity (LDA), as recommended by the treat-to-target approach, has shown to yield improvement in symptoms and quality of life. However, limited evidence from real-world settings is available to support the premise that better disease control is associated with lower healthcare costs. This study fills in evidence gaps regarding the cost of care by RA disease activity (DA) states and by therapy.

Methods

This retrospective cohort study linked medical and prescription claims from Optum Clinformatics Data Mart to electronic health record data from Illumination Health over 1/1/2010-3/31/2020. Mean annual costs for payers and patients were examined, stratifying on DA state and baseline use

SUBMITTER: Curtis JR 

PROVIDER: S-EPMC9510082 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature